Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma
2020-004426-36Phase 2Active
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in Kaposi sarcoma (KS), sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoint: Overall response rate. Started Jun 2021; status: active.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on 2020-004426-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004426-36.